Cardiovascular Considerations of Remdesivir and Favipiravir in the Treatment of COVID-19

Title:Cardiovascular Considerations of Remdesivir and Favipiravir in the Treatment of COVID-19

Volume: 21 Issue: 2

Author(s): Mohammad Amin Shahrbaf, Mohammadreza Tabary and Isa Khaheshi*

Affiliation:

• Cardiovascular Research Center, Shahid Beheshti University of Medical Sciences, Tehran,Iran

Keywords: Remdesivir, favipiravir, COVID-19, heart, cardiovascular, side effect.

Abstract: After the outbreak of COVID-19, many novel drugs have been introduced to improve patients’ conditions. Remdesivir and Favipiravir are among the most common drugs used against SARS-CoV-2. Although promising, cardiovascular side effects of these drugs should be considered by physicians and nurses. In this study, we searched databases for assessing the cardiovascular side effects of Remdesivir and Favipiravir. It seems that despite the beneficial effects of these drugs, due to the cardiovascular complications of COVID-19 and cardiovascular side effects of these drugs, which can overlap with each other, the use of these drugs can be a challenging issue in the cardiovascular practice.

Cite this article as:

Shahrbaf Amin Mohammad, Tabary Mohammadreza and Khaheshi Isa*, Cardiovascular Considerations of Remdesivir and Favipiravir in the Treatment of COVID-19, Cardiovascular & Hematological Disorders-Drug Targets 2021; 21 (2) . https://dx.doi.org/10.2174/1871529X21666210812103535